The content on this site is intended for healthcare professionals only
ESMO 2021: Latest in EGFR mutated advanced NSCLC
Dr Anna Minchom, Prof Natasha Leighl, Dr Victor Moreno and Dr Carlos Cabrera
11 Oct 2021
First-line nivolumab + ipilimumab + chemo in patients with advanced NSCLC and br...
Dr David Paul Carbone - The Ohio State University Medical Center, Ohio, USA
6 Oct 2021
Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSC...
Dr Pascale Tomasini and Dr Catherine Shu
27 Sep 2021
Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs
Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
23 Sep 2021
IMpower010: A Phase 3 study of atezolizumab vs best supportive care after adjuva...
Dr Enriqueta Felip - Vall d’Hebron University Hospital & Vall d’Hebron Institute...
23 Sep 2021
ESMO 2021 Roundup
Dr Bishal Gyawali - Queen's University, Kingston, Canada
22 Sep 2021
Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity
Dr Danny Nguyen - City of Hope, Orange County, USA
21 Sep 2021
OncoAlert and ecancer - ESMO 2021 Day 3
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
19 Sep 2021
OncoAlert and ecancer - ESMO 2021 Day 2
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
18 Sep 2021
ESMO President: What to watch for at ESMO 2021
Prof Solange Peters - ESMO President
17 Sep 2021
Nivolumab plus ipilimumab shows benefit over chemo for unresectable malignant pl...
Prof Solange Peters - Lausanne University Hospital, Lausanne, Switzerland
17 Sep 2021
OncoAlert and ecancer weekly round up for August 2 - August 14, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
16 Aug 2021